Is the worst over? Catal­ent touts GLP-1 and gene ther­a­py busi­ness as it sticks to fi­nan­cial guid­ance

Catal­ent’s fi­nan­cial health ap­pears to be on the mend thanks to spe­cif­ic seg­ments of its man­u­fac­tur­ing busi­ness, but the CD­MO still has a long road to re­cov­ery.

In a sur­prise to an­a­lysts and ob­servers, Catal­ent reaf­firmed its full fis­cal 2024 guid­ance, fore­cast­ing rev­enue of $4.3 bil­lion to $4.5 bil­lion. Part of the growth fore­cast for 2024 is at­trib­uted to a string of new an­tic­i­pat­ed reg­u­la­to­ry ap­provals for ther­a­pies which it is con­tract­ed to man­u­fac­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER